Companies Dominating the Lassa Fever Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Novartis International AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Abbott Laboratories
- Inovio Pharmaceuticals Inc
- Cipla Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of lassa fever treatment is evaluated at USD 120.44 million.
The lassa fever treatment market size was valued at USD 107.14 million in 2024 and is expected to reach USD 630.02 million by 2037, expanding at around 14.6% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of lassa fever and growing awareness about the disease of oil will boost the market growth.
Middle East and Africa industry is poised to dominate majority revenue share of 33% by 2037, impelled by rapid spread of disease in the region.
"The major players in the market are Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited, and others."
